Picture loading failed.

Anti-MSLN therapeutic antibody (Pre-made Amatuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-020-1mg 1mg 3090
GMP-Bios-ab-020-10mg 10mg 21890
GMP-Bios-ab-020-100mg 100mg 148000
GMP-Bios-ab-020-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MSLN therapeutic antibody (Pre-made Amatuximab biosimilar,Whole mAb)
INN Name Amatuximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure4f33:BA:DC:FE:HG/4f3f:BA
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesEisai Co Ltd;Morphotek;National Cancer Institute (USA)
Conditions Approvedna
Conditions ActiveMesothelioma
Conditions DiscontinuedPancreatic cancer;Solid tumours
Development Techna